Invitrogen™ Human DR5 (aa 255-270) Synthetic Peptide

Description

• Human DR5 (residues 255-270) Synthetic Peptide, PEP-048, from Invitrogen
• DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis
• DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain
• DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal
• Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5
• Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found
• Overexpression of DR5 induces apoptosis and activates NF-kappa-B
• DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen
• Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome
• PEP-048 is a 17 amino acid synthetic peptide whose sequence corresponds to residues 255-270 of human DR5
• The sequence of this peptide is (amino to carboxy terminus): C-V255-P-E-Q-E-M-E-V-Q-E-P-A-E-P-T-G270 (The N-terminal cysteine has been added to facilitate conjugation and is not a part of the native human DR5 sequence)This peptide may be used for neutralization and control experiments with the polyclonal antibody that reacts with this product and DR5, catalog &Num PA1-957
• Using a solution of peptide of equal volume and concentration to the corresponding antibody will yield a large molar excess of peptide (∽70-fold) for competitive inhibition of antibody-protein binding reactions.Reconstitute with 0.1 mL of distilled water.